Factor / Lang / Weiner Drug Induced Movement Disorders

2. Auflage 2008
ISBN: 978-1-4051-3755-3
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 480 Seiten, E-Book

The second revised edition of this text will update and present current state of the art clinical approaches to this subject. This book will continue to be the source text of information on drug-induced movement disorders authored and edited by the pioneers in the field. It will be an invaluable addition to the library of any neurologist.

Autoren/Hrsg.

Factor, Stewart

Lang, Anthony

Weiner, William

Inhaltsverzeichnis

Section 1: General Considerations.
Chapter 1: Movement Disorders: Approach, Definitions anddifferential Diagnosis.
Martin Cloutier, Anthony E. Lang.
Chapter 2: Rating Scales for Movement Disorders.
Wonodi I, Hong EH, Avila MT, Gunvant Thaker.
Chapter 3: Spontaneous movement disorders in psychiatricpatients.
Irene Richard, Christopher O'Brien, RogerKurlan.
Section 2: Antipsychotics.
Chapter 4: Pharmacology of typical and atypical agents.
Gary Remington, Shitij Kapur.
Chapter 5: Acute Drug-induced Dystonia.
Michael F. Mazurek, Patricia I. Rosebush.
Chapter 6: Drug-Induced Parkinsonism.
Joseph H. Friedman, Martha E. Trieschmann, Hubert H.Fernandez.
Chapter 7: Acute Akathisia.
Author: Lenard A. Adler, John Rotrosen, Burt Angrist.
Chapter 8: Neuroleptic Malignant Syndrome.
Stewart A. Factor.
Chapter 9: Classical Tardive Dyskinesia.
Thomas M. Hyde, MD, Jose A. Apud, Whitney C. Fisher, MichaelF. Egan.
Chapter 10: Tardive dyskinesia Variants.
Skidmore F, Weiner W, Burke R.
Chapter 11: Movement Disorders caused by atypicalantipsychotics.
Karen E. Anderson.
Chapter 12: Commentary: Is Tardive dyskinesiadisappearing?James Lohr, MD.
.
.
Section 3: Dopaminomimetic Drugs.
Chapter 13: Dyskinesia induced by levodopa and dopamine agonistsin Parkinson's disease.
John G. Nutt, Matthew Brodsky.
Chapter 14: Stimulant Drugs.
Anthony E. Munson, Juan Sanchez-Ramos, William JWeiner.
Section 5: Other Drugs.
Chapter 15: Antidepressants.
Marie L. Moro-de-Casillas, David E. Riley.
Chapter 16: Anticonvulsants.
John C. Morgan, Madeline Harrison.
Chapter 17: Miscellaneous Drugs.
Daniel Tarsy

Über Autor(innen)

Dr. Stewart Factor, DO. Professor of Neurology, Riley Family Chairin Parkinson's Disease, Director, Parkinson's Disease andMovement Disorder Program, Albany Medical Center
Dr. Anthony E. Lang, MD. Movement Disorder Clinic, TorontoWestern Hospital
Dr. William J. Weiner, MD. Chair, Department ofNeurology, University of Maryland School of Medicine